Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P1.07-010 - Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
09:30 - 09:30 | Presenter: Junko Tanizaki | Author(s): K. Haratani, Hidetoshi Hayashi, Y. Chiba, Kimio Yonesaka, K. Kudo, H. Kaneda, Y. Hasegawa, K. Tanaka, M. Takeda, Kazuhiko Nakagawa
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.03 - Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
16:05 - 16:15 | Presenter: Keunchil Park | Author(s): K. Azuma, C. Tsai, Takashi Seto, H. Nokihara, James Chih-Hsin Yang, Sang-We Kim, H. Murakami, Makoto Nishio, K. Kiura, A. Inoue, K. Takeda, Jin-Hyoung Kang, Hidetoshi Hayashi, T. Nakagawa, Y. Kaneko, R. Akazawa, M. Shimazaki, S. Morita, M. Fukuoka, Kazuhiko Nakagawa
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P2.03-008 - Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L
09:30 - 09:30 | Presenter: Tatsuo Kimura | Author(s): Tomoya Kawaguchi, S. Kudoh, Y. Chiba, H. Yoshioka, K. Watanabe, T. Kijima, Y. Kogure, T. Oguri, Naruo Yoshimura, T. Niwa, T. Kasai, Hidetoshi Hayashi, A. Ono, H. Tanaka, S. Yano, S. Nakamura, Nobuyuki Yamamoto, Yoichi Nakanishi, Kazuhiko Nakagawa
- Abstract
Loading... -
+
P2.03-045 - Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR)
09:30 - 09:30 | Presenter: Hidetoshi Hayashi | Author(s): H. Akamatsu, Y. Koh, S. Morita, Daichi Fujimoto, Isamu Okamoto, A. Bessho, K. Azuma, Kazuhiko Nakagawa, Nobuyuki Yamamoto
- Abstract
Loading... -
+
P2.03-058a - T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC
09:30 - 09:30 | Presenter: Takeshi Yoshida | Author(s): S. Watanabe, H. Kawakami, N. Takegawa, Junko Tanizaki, Hidetoshi Hayashi, M. Takeda, Kimio Yonesaka, J. Tsurutani, Kazuhiko Nakagawa
- Abstract
No abstract available for this presentation
-
+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P2.07-021 - A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Kimio Yonesaka | Author(s): K. Kudoh, S. Takamura, H. Sakai, R. Kato, K. Haratani, T. Takahama, K. Tanaka, Hidetoshi Hayashi, H. Kaneda, M. Takeda, O. Maenishi, M. Yamato, M. Miyazawa, Kazuto Nishio, Kazuhiko Nakagawa
- Abstract
Loading...
